Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma | Zendy

Laura Maggino | Zendy; Giuseppe Malleo | Zendy; Giovanni Marchegiani | Zendy; Elena Viviani | Zendy; Chiara Nessi | Zendy; Debora Ciprani | Zendy; Alessandro Esposito | Zendy; Luca Landoni | Zendy; Luca Casetti | Zendy; Massimiliano Tuveri | Zendy; Salvatore Paiella | Zendy; Fabio Casciani | Zendy; Elisabetta Sereni | Zendy; Alessandra Binco | Zendy; Deborah Bonamini | Zendy; Erica Secchettin | Zendy; A. Auriemma | Zendy; Valeria Merz | Zendy; Francesca Simionato | Zendy; Camilla Zecchetto | Zendy; Mirko D’Onofrio | Zendy; Davide Melisi | Zendy; Claudio Bassi | Zendy; Roberto Salvia | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

Author(s) -

Laura Maggino,

Giuseppe Malleo,

Giovanni Marchegiani,

Elena Viviani,

Chiara Nessi,

Debora Ciprani,

Alessandro Esposito,

Luca Landoni,

Luca Casetti,

Massimiliano Tuveri,

Salvatore Paiella,

Fabio Casciani,

Elisabetta Sereni,

Alessandra Binco,

Deborah Bonamini,

Erica Secchettin,

A. Auriemma,

Valeria Merz,

Francesca Simionato,

Camilla Zecchetto,

Mirko D’Onofrio,

Davide Melisi,

Claudio Bassi,

Roberto Salvia

Publication year - 2019

Publication title -

jama surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.757

H-Index - 176

eISSN - 2168-6262

pISSN - 2168-6254

DOI - 10.1001/jamasurg.2019.2277

Subject(s) - medicine , folfirinox , gemcitabine , oxaliplatin , chemotherapy , oncology , adenocarcinoma , regimen , pancreatic cancer , surgery , cancer , colorectal cancer

Chemotherapy is the recommended induction strategy in borderline resectable and locally advanced pancreatic ductal adenocarcinoma. However, the associated results on an intention-to-treat basis are poorly understood.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research